Nanotechnology to allow for ‘low-cost’ diagnostics and therapeutics for diseases like cancer
There are more than 40 nanodrugs on the market, most for cancer, but now the challenge is to lower costs so they can be integrated into the healthcare system.
By Biocat
"One of the aims of nanotechnology is to sequence an individual’s genome in one hour for $100 by 2020," explained Yoshinobu Baba of Nagoya University (Japan) this week at the scientific debates Nanotechnologies in Health: Current Challenges and Future Prospects organized by B·Debate, the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and the Institute of Biotechnology and Biomedicine (IBB-UAB) in Barcelona. The event featured more than 60 national and international experts.
From 9 to 11 October these scientists debated on available nanomedical tools, how to continue promoting innovation in this field and, above all, how to accelerate application in patients. Nanotechnology is a booming area of research with great potential in many sectors. In medicine, it promises to revolutionize the diagnosis of diseases, drug delivery and many areas of research, development and clinical application. "Trials based on nanomaterials are promising for cancer diagnosis," said Joseph Wang, keynote speaker at the debates and professor of Nanoengineering at the University of California, San Diego (United States).
More information on the B·Debate website.
Follow the debate on Twitter @BDebate with the hashtag #BDebate.
- Related news (8 October 2013)
- Related press release (4 October 2013)
- News on other B·Debate activities
| Organizers: |
   |
| Collaborators: |
    |